Gyre Therapeutics EVP reports stock option holdings
GYRE THERAPEUTICS, INC. executive vice president and general manager Jialiang Wang has reported initial holdings of stock options for the company’s common stock.
Rhea-AI Filing Summary
GYRE THERAPEUTICS, INC. executive vice president and general manager Jialiang Wang has reported initial holdings of stock options for the company’s common stock. The Form 3 shows options covering 47,530 underlying shares at an exercise price of $5.98 per share expiring on November 12, 2034, 42,777 underlying shares at $2.00 expiring on April 16, 2031, 38,024 underlying shares at $0.93 expiring on January 12, 2030, and 95,060 underlying shares at $0.32 expiring on June 7, 2028, all held directly. A footnote states that one of these options is fully vested, while another vests over time starting on November 13, 2025, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Wang Jialiang (NMN)
Role
EVP, General Manager
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 223,391 contracts (Direct)
Footnotes (2)
- F1. This option is fully vested.
- F2. This option represents a right to purchase 47,530 shares of the Issuer's common stock, one quarter of which vested on November 13, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Option underlying shares: 47,530 shares at $5.98
Option underlying shares: 42,777 shares at $2.00
Option underlying shares: 38,024 shares at $0.93
+1 more
4 metrics
Option underlying shares
47,530 shares at $5.98
Exercise price $5.98; expiration November 12, 2034
Option underlying shares
42,777 shares at $2.00
Exercise price $2.00; expiration April 16, 2031
Option underlying shares
38,024 shares at $0.93
Exercise price $0.93; expiration January 12, 2030
Option underlying shares
95,060 shares at $0.32
Exercise price $0.32; expiration June 7, 2028
Key Terms
Stock Option (Right to Buy), exercise price, underlying security, Form 3
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" over common stock"
exercise price financial
"conversion_or_exercise_price fields list each option’s exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
underlying security financial
"underlying_security_title is reported as "Common Stock""
Form 3 regulatory
"Initial statement of beneficial ownership of securities on Form 3"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Gyre Therapeutics (GYRE) Form 3 for Jialiang Wang report?
The Form 3 reports EVP and general manager Jialiang Wang’s initial beneficial ownership in Gyre Therapeutics stock options. It lists several option grants over common shares, with specific exercise prices, expiration dates, and direct ownership, but no new stock purchases or sales.
What are the exercise prices of Jialiang Wang’s Gyre Therapeutics stock options?
The options have exercise prices of $5.98, $2.00, $0.93, and $0.32 per share. These prices indicate the levels at which Wang can purchase Gyre Therapeutics common stock under each grant, subject to vesting and expiration terms.
When do Jialiang Wang’s Gyre Therapeutics stock options expire?
The reported options expire on June 7, 2028, January 12, 2030, April 16, 2031, and November 12, 2034. These staggered expiration dates illustrate a long-term equity incentive structure tied to Wang’s ongoing service with Gyre Therapeutics.
Are Jialiang Wang’s Gyre Therapeutics stock options fully vested?
One footnote states that an option is fully vested, while another describes an option for 47,530 shares that vests partially on November 13, 2025 and then in equal monthly installments over three years, contingent on Wang’s continued service at Gyre Therapeutics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
